The Need for Novel Therapeutic Directions in Autosomal Dominant Polycystic Kidney Disease Patient Care

A late-2025 review maps the expanding ADPKD treatment pipeline beyond tolvaptan, including repurposed SGLT2 inhibitors, metformin and GLP-1 receptor agonists, novel molecular agents such as a polycystin-1 corrector and a microRNA-17 inhibitor, dietary strategies, and early gene therapy, signalling a shift toward disease-modifying and potentially curative approaches.